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ABSTRACT
Lack of access to health care is often blamed for poor health outcomes, but this effect is not
supported by existing HIV/AIDS literature. The authors examined the association between
access to care and survival time after progression to AIDS, using survival analysis methods.
This study combined data from two CDC sponsored studies of HIV-infected persons, a cross-
sectional interview study and a longitudinal medical record review study. Study subjects in-
cluded 752 persons who progressed to AIDS before December 31, 1999, and were patients at
either of two major HIV care facilities in Detroit, MIchigan. Separate statistical models were
used to test associations between survival time after meeting the criteria for AIDS and two
indicators of access to health care: (1) perceived access to health care and (2) health care uti-
lization patterns. Perceived access was not associated with survival time after AIDS, but pat-
terns of health care utilization were significantly associated with survival time after AIDS
(HR 5 2.04, p , 0.001). Individuals who received a greater proportion of their care in the ER
had a worse survival prognosis than those who received more of their health care in an out-
patient clinic setting. It is crucial that we provide HIV-infected populations with tools that
enable them to access a regular source of health care.
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INTRODUCTION
DIFFERENCES IN SURVIVAL TIME of HIV in-fected persons are often attributed to dif-
ferences in access to health care.1,2 While this
explanation is logical and supported for other
disease processes, there is little evidence in the
literature to support the conclusion that better
access to health care improves survival prob-
ability in people living with AIDS. Some stud-
ies have shown that perceived access to health
care was associated with health-related qual-
ity of life measures.3,4 It is important to study
the factors that give rise to differences in sur-
vival time in the United States so that survival
can continue to improve. The recent survival
gains, which are often associated with newly
available antiretroviral drugs, differ signifi-
cantly among blacks, whites, men and
women.5,6 If the factors responsible for these
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differences can be determined, they may then
be modified.
Drug therapies from the mid-1990s changed
the picture of the AIDS epidemic in the United
States. The availability of new antiretroviral
drugs and highly active antiretroviral therapy
(HAART) in the United States since 1996 has
lead to a significant reduction in HIV-related
morbidity and mortality.7–10 Incidences of
AIDS-defining opportunistic illnesses have sig-
nificantly decreased with the introduction of
these combination therapies.5,11 Clearly, access
to these medications extends survival time, but
antiretrovirals are very expensive. Private in-
surance providers, health maintenance organi-
zations, and public programs offer assistance
with the cost of these drugs. Attempts to tar-
get under-represented populations for in-
volvement in clinical trials for new antiretrovi-
ral drugs through the Terry Beirn Community
Programs for Clinical Research on AIDS
(CPCRA) have also helped to close the gap in
access to HIV-related treatment.1
In this article, we examine perceived access
to health care and utilization of health services
and their associations with survival after AIDS,
controlling for HAART status. We hypothe-
sized that indicators of access to health care
(both perceived access to care and health care
utilization) were significantly associated with
survival.
METHODS
This study was conducted under the aus-
pices of the Michigan Department of Commu-
nity Health’s HIV/AIDS Surveillance Section,
located in Detroit, Michigan. The databases
from two surveillance studies were matched:
the Adult/Adolescent Spectrum of HIV Dis-
ease (ASD) project, and the Supplement to HIV
and AIDS Surveillance (SHAS) project. Both
ASD and SHAS are ongoing multi-site projects,
located throughout the United States. This
study examines data from the two Detroit,
Michigan sites. These facilities offer inpatient,
outpatient, and emergency care for HIV-in-
fected patients, and are the major HIV care
providers in Southeastern Michigan. Candi-
dates for inclusion in this project were at least
18 years of age at the time of their SHAS in-
terview, had completed a SHAS interview, and
had an ASD record.
ASD is a surveillance study, initiated in
1990.12 Data from all medical records available
at the two Detroit sites were abstracted in 6-
month intervals from the time an HIV-infected
person presented for care at one of the partici-
pating facilities until he/she died or was lost
to follow-up. Medical records for any visit to
these facilities were included. Information was
collected on HIV-related illnesses, other med-
ical conditions, drug therapies, laboratory tests
(including CD4 counts), and health care uti-
lization. At one site, all HIV-infected men and
women who presented for care were included
in ASD. At the other site, all HIV-infected
women but only 40% of HIV-infected men were
included in ASD, owing to a large number of
male patients. Between January, 1990 and De-
cember, 1999, approximately 4,600 patients
were included and followed as part of the De-
troit ASD study.
Initiated in 1990, SHAS is a cross-sectional
interview-based surveillance project of persons
with HIV or AIDS reported to the state health
department.13 The SHAS study collected infor-
mation on demographics, health insurance, so-
cio-economic status, sexual behavior, drug use,
reproductive history, and adherence to drug
therapies. SHAS candidates were identified as
HIV positive at the care facilities and were ap-
proached for an interview by a full-time,
trained SHAS interviewer. Informed consent
was obtained before all interviews. The refusal
rate for SHAS was approximately 2%. Between
June, 1990 and December, 1999, approximately
2,000 patients were interviewed as part of the
Detroit SHAS study.
In Michigan, ASD and SHAS are linked to
the HIV/AIDS Reporting System (HARS).
HARS is the surveillance registry that contains
all reported cases of HIV and AIDS. The
ASD/SHAS matched database was created by
merging ASD and SHAS based on a numerical
identifier that links both studies to HARS. The
ASD and SHAS subjects were demographically
similar to HIV and AIDS cases in the Detroit
metropolitan area (ASD was 72% male, 70%
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black, and 65% age 20–40; SHAS was 77% male,
74% black, and 64% age 20–40; HARS in the De-
troit metropolitan area was 78% male, 69%
black, and 62% age 20–40). Institutional Review
Board approval or exemption from review was
granted for ASD, SHAS, and the matched data-
base study. The ASD/SHAS matched database
included records for 1550 people.
Combination therapy (HAART), which in-
cludes three classes of antiretrovirals [nucleo-
side reverse transcriptase inhibitors (NRTI),
protease inhibitors (PI), and non-nucleoside re-
verse transcriptase inhibitors (NNRTI)], has
had a significant impact on survival time in
people living with AIDS. In 1996, the FDA ap-
proved the first protease inhibitor through its
fast track approval process. While protease in-
hibitors became available in 1996, the United
States Public Health Service did not establish
treatment guidelines, which recommended
triple drug therapy, until 1998.14 Since specific
regimens and dates of antiretroviral usage
were not collected in ASD until 1998, we were
limited in our ability to categorize HAART. We
defined HAART as prescription of at least three
antiretroviral drugs in a specified 6-month in-
terval, whether or not these were prescribed si-
multaneously. For this study, subjects were di-
vided into the following two categories: (1)
those who were not prescribed HAART, as de-
fined for this study (the “no HAART” group)
and (2) those who have ever been prescribed
HAART, as defined for this study (the
“HAART” group). Every person in this study
fits into one of these two mutually exclusive
categories.
The health outcome variable examined was
survival time. For the purpose of obtaining a
relatively consistent beginning point for each
person, survival was measured from the date
a person first met the criteria for AIDS to time
of death. A consistent AIDS definition was
used for all persons to avoid the bias that
would result from a sudden increase in the
number of AIDS cases in 1993 when the AIDS
definition was expanded. For all persons, the
1993 AIDS case surveillance definition15 was
used, which includes laboratory-based criteria
(CD4 count ,200 or ,14%/mL of blood) and
clinical criteria (AIDS-defining opportunistic
illnesses). For persons in ASD before 1993, the
1993 case definition could still be applied be-
cause all necessary data (CD4 count, pul-
monary TB, invasive cervical cancer, and re-
current pneumonia) were available since the
ASD study began in 1990.
Vital status was collected for the ASD data-
base from the following sources: (1) medical
record documentation of death, (2) information
from Michigan and Detroit death registries,
and (3) report of AIDS-related deaths to the
Michigan HARS from other hospitals (those
not participating in ASD). Because we made an
extensive search of death records, we assumed
that any patient not known to have died, or to
be lost to follow-up, was alive as of December
31, 1999. Those who were lost to follow-up be-
fore December 31, 1999 were censored as of the
date of their last visit.
Two separate survival analysis models were
used, one that included indicators for per-
ceived access to health care and one that in-
cluded an indicator for utilization of health care
services. The health outcome variable in both
models was survival time after AIDS, and race,
sex, and mode of transmission were included
as predictor variables. Greater than 97% of the
subjects reported belonging to either black or
white racial groups, therefore other racial and
ethnic categories were excluded from these
analyses. Age at time of AIDS was included as
a continuous variable. The first survival analy-
sis model examined perceived access to health
care based on three questions: (1) In the past 12
months, have you ever been denied medical
care for HIV infection or AIDS because you
could not pay for treatment (yes/no)? (2) In the
past 12 months, have you not sought medical
care for HIV infection or AIDS because you
couldn’t pay for it (yes/no)? (3) Do you cur-
rently have health care insurance, including
government-sponsored insurance such as Med-
icaid (yes/no)? Responses to these questions
from the SHAS interview were used as di-
chotomous variables for the survival analysis
models.
The second survival analysis model focused
on health care utilization as measured by the
total number of visits to the emergency room
(ER) divided by the total number of visits to
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both the ER and outpatient clinics. There were
no patients in this study who sought care ex-
clusively through the emergency department.
This ratio demonstrates the care-seeking be-
havior of each individual. A person who used
the ER as a primary source of health care had
a very different care-seeking profile than a per-
son who utilized a regular health care provider
and who sought regular outpatient appoint-
ments.
We used the Centers for Disease Control and
Prevention (CDC) defined mode of transmis-
sion categories16: (1) Men who have sex with
men who are also injection drug users
(MSM/IDU), (2) men who have sex with men
(MSM), (3) injection drug users (IDU), (4) re-
cipients of blood products (transfusion, organ
transplant, hemophilia related blood products,
etc.), (5) individuals who engage in heterosex-
ual sex, and (6) those with no identified risk
(NIR). These categories of risk were applied hi-
erarchically, resulting in mutually exclusive cat-
egories.16 For the purpose of these analyses,
MSM/IDU, blood products, and heterosexual
sex were combined into one category (referred
to as “other”). Preliminary analyses (not shown)
demonstrated that these modes of transmission
had relatively small sample sizes and were not
significantly associated with survival. Dummy
variables for IDU, NIR and “other” (compared
to MSM) were used for the survival models.
MSM was generally used as the referent cate-
gory for mode of transmission in the litera-
ture.17–21
Cause of death was not examined, because it
was not available for all cases known to have
died. However, cause of death was available
for 58% of deaths in the ASD database (of
which this study was a subset). Of those with
a known cause of death, approximately 87%
were HIV-related. The number of deaths not
due to HIV-related causes were evenly distrib-
uted between the treatment groups, suggesting
that the probability of death being HIV-related
did not change significantly with HAART.
Cox proportional hazard models were used
to examine the association between predictor
variables and survival time, with ties handled
by Efron’s method. Only post-SHAS ques-
tionnaire survival time was considered, and
survival analysis methods for delayed entry
(i.e., left truncation) were employed.22 Log
minus log survival curves were plotted
against time for each covariate to determine
the appropriateness of the proportional haz-
ards assumption.22 Where the proportional
hazards assumption was not appropriate, sev-
eral time-dependent functions were tested to
find the model that best fit the data.23 Inter-
actions between variables in the models were
tested and t-tests were used to check for col-
inearity. Data analyses were performed using
SAS Software and S-Plus.24,25
RESULTS
Of the 1,550 subjects included in the
ASD/SHAS matched database between Janu-
ary, 1990 and December 1999, this study in-
cluded the 752 people who met the definition
for AIDS, and for whom complete data were
available for the variables examined. Approxi-
mately 35% of subjects had received HAART,
72% were black, 78% were male, and 54% were
MSM. Responses to the access to health care
questions were distributed as follows: 4.0%
were denied medical care because they could
not pay, 7.5% did not seek medical care because
they could not pay, and 7.5% did not have cur-
rent health insurance at the time of their SHAS
interview. While there was some overlap in re-
sponses to these questions (34% were denied
care and did not seek care because they could
not pay, 16% were denied care because they
could not pay and had no health insurance, and
20% had no health insurance and did not seek
care because they could not pay), those who
were denied medical care were not necessarily
the same subjects who did not seek care or did
not have health insurance.
For each covariate, log minus log survival
plots were examined and confirmed that haz-
ards were proportional for race, sex, mode of
transmission, the three indicators of access to
care, and the health care utilization variable.
However, hazards did not appear to be pro-
portional for HAART. Multiple time-depen-
dent models were tested to determine the best
representation of the functional form of
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HAART. The time-dependent covariate used
was HAART 3 survival time.
The methodology for defining HAART was
crude, thus we tested the validity of this
HAART definition using just the ASD database
(n 5 1,709). We found that HAART was asso-
ciated with a threefold increase in survival
time, which is similar to that described in the
literature.7–10
Indicators of perceived access to health care
and utilization of health care were explored in
separate Cox proportional hazards models. The
perceived access-based Cox model included
race, sex, mode of HIV transmission, HAART,
time-dependent HAART, denial of care due to
an inability to pay, not seeking care because of
an inability to pay, and health insurance status.
The utilization-based Cox model included race,
sex, mode of HIV transmission, ER visit ratio,
HAART, and its corresponding time dependent
covariate. For each variable, the estimate and
significance were robust to changes in other co-
variates in the model. Table 1 shows the results
from the perceived access model, and Table 2
shows the results of the utilization model.
HAART was a significant predictor of sur-
vival in both the access (Table 1) and utiliza-
tion (Table 2) models, p , 0.001. The associa-
tion between HAART and survival changed
over time as illustrated by a significant time-
dependent covariate in each model. [Hazard
ratios (HR) in the access-based model: HR at 1
year 5 0.12, 2 years 5 0.14, 5 years 5 0.23, 
8 years 5 0.37. HR in the utilization-based
model: HR at 1 year 5 0.12, 2 years 5 0.14, 5
years 5 0.22, 8 years 5 0.35.] HAART was con-
sistently associated with improved probability
of survival, although this association tended
toward the null as survival time increased.
In the first survival analysis model, the per-
ceived access to health care model (Table 1),
none of the indicators of access to health care
were significantly associated with survival
time after AIDS. Additionally, we tested a
model in which any one response indicating
poor perceived access to care constituted the
access variable. This model was also not sig-
nificant, indicating that the lack of association
was not due to inadequate power.
In the second survival analysis model, the
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TABLE 1. PERCEIVED ACCESS TO HEALTH CAREa
Hazard ratio (HR)
Predictor variable (n 5 752; 552 deaths) P-value
Denied care because unable to pay 0.69 0.119
(denied care vs. not denied care)
Not sought care because unable to pay 1.10 0.588
(not sought care vs. sought care)
Health Insurance 1.01 0.961
(insurance vs. no insurance)
HAART (referent 5 HAART) ,0.001b
Time dependent (HAART 3 time) 0.020c
HR at 1 year 0.12
HR at 2 years 0.14
HR at 5 years 0.23
HR at 8 years 0.37
Race (referent 5 white) 0.86 0.123




No identified risk 1.00 0.977
Other 0.93 0.606
aCox proportional hazards model for the relative hazard of death in AIDS patients.
bp , 0.0005.
cp , 0.05.
HAART, highly active antiretroviral therapy; MSM, men who have sex with men;
IDU, injection drug users.
utilization of health care model (Table 2), the
ratio of ER visits to the total number of ER and
outpatient visits was significantly associated
with survival time (p , 0.001). Also, in this
model, white race was significantly associated
with increased probability of survival (HR 5
0.79, p 5 0.020).
t-Tests were used to test for colinearity be-
tween the perceived access and utilization in-
dicators. Colinearity was detected between the
utilization indicator (ER visit ratio) and two of
the three indicators of access to health care (not
seeking care because of inability to pay and
health insurance status). A lower ER visit ratio
indicated that a smaller proportion of health
care visits occurred in the ER than in the out-
patient clinic. The ER visit ratio was lower for
those who did not report financial barriers to
seeking care than for those who did not seek
care because of inability to pay. The mean ER
visit ratio was 0.17 [standard deviation (SD) 5
0.24] for those who did not avoid seeking
health care due to an inability to pay versus
0.27 (SD 5 0.31) for those who did avoid seek-
ing health care because they could not pay, and
the t-test had a p value 5 0.019. For those who
had health insurance, the ER visit ratio was
lower than for those who did not have insur-
ance. The mean ER visit ratio was 0.17 (SD 5
0.24) for those with health insurance versus
0.29 (SD 5 0.33) for those who did not have
health insurance, and the t-test p-value 5 0.011.
DISCUSSION
In this study we examined the association be-
tween survival after AIDS and indicators of
perceived access to health care and utilization
of health services. We observed that the indi-
cator for utilization of health care and race (in
the utilization model only) were significantly
associated with survival after AIDS, but that
sex, mode of transmission, and perceived ac-
cess to health care were not significantly asso-
ciated with survival in the study population.
These results affirm the hypothesis posed by
other researchers that utilization of health care
services was an underlying source of differ-
ences in survival previously attributed to race,
sex, or mode of transmission.1,2
HAART was a significant predictor of sur-
vival in both models. This is consistent with
previous studies that found HAART to be as-
sociated with decreased morbidity and mortal-
ity in HIV-infected populations.7–11 We also
found that the association between HAART
and survival decreased over time after AIDS.
We attribute this to the long-term non-pro-
gressors who were infected prior to the avail-
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TABLE 2. UTILIZATION OF HEALTH CAREa
Hazard ratio (HR)
Predictor variable (n 5 752; 552 deaths) P-value
ER visit ratio (ER visits/total ER 1 outpatient visits) 2.04 ,0.001b
HAART (referent 5 HAART) ,0.001b
Time dependent (HAART 3 time) 0.035c
HR at 1 year 0.12
HR at 2 years 0.14
HR at 5 years 0.22
HR at 8 years 0.35
Race (referent 5 white) 0.79 0.020c




No identified risk 0.99 0.930
Other 0.89 0.425
aCox proportional hazards model for the relative hazard of death in AIDS patients.
bp , 0.0005.
cp , 0.05.
HAART, highly active antiretroviral therapy; MSM, men who have sex with men; IDU, injection drug users; ER,
emergency room.
ability of HAART and lived without HAART
for many years, thus narrowing the gap in sur-
vival time between the two treatment groups.
This finding is reminiscent of the mortality
crossover effect discussed by Wing and col-
leagues.26 They described mortality ratios that
change over time with the force of mortality
operating earlier in some populations than in
others. Over time, the healthy and resilient of
a group remain alive, and the mortality ratio
eventually reaches unity.
Individual perception of access to health care
was not associated with survival. Perceived ac-
cess to health care was measured using three
indicator questions. The indicators that we
used to measure perceived access to health care
may have been inadequate. Andersen and col-
leagues discuss the dimensions of potential and
realized access to medical care and several in-
dicators of these dimensions.27 The perceived
access indicators that we used fall under the
category of potential access and are not com-
plete according to their guide. This may explain
the lack of association between perceived ac-
cess to care and survival that we found. Since
all of our study participants have already ac-
cessed the health care system, utilization of
these services may better predict survival.
Utilization of health care services was mea-
sured as the ratio of ER visits to the total num-
ber of ER and outpatient visits. Previous stud-
ies found that HIV-infected patients had a
much better survival probability if they re-
ceived regular care from providers who spe-
cialized in treating HIV infection, compared to
providers who did not specialize in HIV
care.28,29 Our results were consistent with these
findings. Individuals who received a greater
proportion of their care in the ER had a worse
survival prognosis than those who received
more outpatient care (which was provided by
physicians who specialized in HIV infection).
Perceived access and utilization (ER visit ra-
tio) were not independent indicators of health
care access. Those without insurance went to the
ER more often, and were less likely to have a reg-
ular source of care. Similarly, the group that did
not seek medical care due to inability to pay re-
ceived a greater proportion of their care from the
ER. Because of the colinearity that was detected,
we expected that both perceived access and uti-
lization would significantly predict survival.
Since this was not the case, we conclude that the
access to care indicators were inadequate.
There are several limitations of this study.
First, the ASD database relies on what was
recorded in medical records at the two study
sites to completely represent the history of each
patient’s HIV care. Patients may have been seen
for HIV care at additional facilities and that in-
formation would not be available. HAART mis-
classification may have occurred in cases where
HAART was prescribed at non-ASD facilities,
and not included in the medical records at the
ASD facilities.
A second limitation is that SHAS interviews
were done only once and at varying times
throughout each persons disease process,
which may have caused additional bias in the
study. However, by limiting SHAS variables to
those which should not change over time (e.g.,
race), or change minimally (e.g., access to
health care and utilization of health services)
such bias was minimized. Additionally, in the
survival analysis models data were left trun-
cated taking into consideration when the SHAS
interview occurred. This method adjusts for the
bias that would result from not including those
who died before they had the opportunity to
be interviewed.
A third limitation to the study is that the se-
lection of SHAS participants was not random.
However, all eligible participants were ap-
proached and the refusal rate was low (2%).
Therefore, this should not have a significant
impact on study outcomes.
A fourth limitation is the possibility that
those with a higher proportion of ER visits
were sicker. This would cause them to have
worse survival probability. We attempted to
minimize the resulting bias by including only
individuals who met the criteria for AIDS, thus
presuming high levels of morbidity in the en-
tire population.
Populations that are historically underserved
by the health care system, such as blacks,
women, and injection drug users, are also at
high risk for HIV infection. Cunningham and
colleagues found that access to medical care
was poorer for those with HIV than for other
chronic diseases.4 Consistent with our findings,
other studies have shown that even among in-
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dividuals within the health care system, a reg-
ular source of health care (including clinic ap-
pointments with HIV specialists) increases sur-
vival time for people living with AIDS.28,29 It
is crucial to provide HIV-infected populations
with tools that will enable them to adequately
access a regular source of health care in a way
that will most benefit their health.
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